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Managing glaucoma in developing countries
Lidando com o glaucoma em países em desenvolvimento
MAURO TOLEDO LEITE1, LISANDRO MASSANORI SAKATA2, FELIPE ANDRADE MEDEIROS1,3
HOW BIG IS THE PROBLEM?
A recent estimate of the number of people affected by glaucoma worldwide suggested that by 2020 there
will be approximately 80 million people with the disease, of which 11 million will be bilaterally blind(1). Due to
the paucity of information on disease prevalence in Latin America, estimates of prevalence for this region have
been derived mostly from studies conducted in Hispanic populations living in the United States(1). These
extrapolated prevalence rates are likely to be inaccurate, particularly in Brazil, due to its heterogeneous and
highly racially-mixed population.
Very few data are available on the prevalence of glaucoma in the Brazilian population. A recent population
based-study conducted in the south of Brazil found an overall glaucoma prevalence of 3.4% (95% CI: 2.5% to
4.3%) in a sample of 1,636 subjects over 40 years of age. Open-angle glaucoma (OAG) was the most common
form of the disease with an estimated prevalence of 2.4%, which increased sharply with aging, achieving 4%
in those 60 years of age or older(2). Interestingly, almost 90% of the glaucoma patients were not aware of their
diagnoses, a number that is much higher than estimates of disease awareness previously reported for
developed countries, which have been close to 50%(3-5). As the population in developing countries ages, the
number of individuals with glaucoma will increase, likely worsening the socio-economic burden of the
disease. According to the United Nations estimation, the number of Brazilians over 60 years old is estimated
to grow from approximately 20 million people in 2010 to 64 million in 2050(6). That would represent an
increase from 800,000 people with OAG in 2010 to approximately 2.6 million in 2050.
It is important to emphasize that a study of glaucoma prevalence conducted in the south of Brazil may not
be able to fully characterize the burden of the disease in the whole country, due to the highly heterogeneous
ethnic composition of the Brazilian population according to the regions of the country. For example, in the
study of Sakata et al., 71% of the examined sample was self-declared as White. Non-Whites tended to show
a higher prevalence of OAG and also a higher rate of blindness from the disease compared to Whites, although
estimates of prevalence and blindness in non-Whites were largely imprecise due to the small sample size(2).
It is likely that the overall numbers on prevalence and burden of the disease would be different had the study
been conducted in the northern parts of the country. Population-based epidemiologic studies are essential
in order to provide information on the magnitude of the problem so that adequate strategies can be planned
to deal with it. Such studies can be very costly and, therefore, support from government agencies or other
forms of federal or private support are essential to ensure adequate funding.
DETECTION OF THE DISEASE
As a chronic, progressive and irreversible disease, early detection and treatment of glaucoma are
essential for a good visual prognosis. One of the greatest challenges in diagnosing the disease comes from its
asymptomatic nature until the glaucomatous process reaches an advanced stage. Thus, glaucoma diagnosis is
often performed as case finding in regular ophthalmic consultations. In developing countries, detecting
glaucoma becomes even a more complicated issue due to the limited access to Ophthalmic eye care facilities
by large part of the population. However, it is clear that if we want to reduce the burden of blindness due to
glaucoma, we must improve the detection of the disease.
There are two approaches to detect patients that are unaware of their glaucoma: either make the existing
system work better by improving opportunistic case finding, or change the system by initiating a systematic
population screening program(7). In addition, the health care system needs to ensure enough capacity to
handle the newly detected cases. Recent studies have shown that up to the current time and with currently
available diagnostic techniques, there is not enough evidence to support the cost-effectiveness of a
systematic population screening program, even in developed countries(8).
In Brazil, there is a reasonable public health program to detect and treat systemic arterial hypertension
and diabetes, which includes free distribution of some medications. Unfortunately glaucoma detection may
not be as straightforward as diagnosing systemic hypertension or diabetes. These diseases are relatively
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easier to diagnose, as their main biological variable measurements (arterial blood pressure and glycemia,
respectively) can be evaluated in an objective manner by non-expensive and easy to interpret tests. On the
other hand, glaucoma diagnosis can be quite challenging. It is often necessary to perform multiple exams
that require highly trained professionals to interpret their results, and many parts of the diagnostic criteria
can be considered subjective. Thus, since the availability of resources is limited, it is likely that the best option
at the current time would be to try to improve the awareness of the disease among the general population,
including education about risk factors such as positive family history. Additionally, a better medical education
could also optimize opportunistic case finding.
GLAUCOMA TREATMENT
The ultimate goal of glaucoma treatment is to slow down disease progression to a rate in which the patient
will not experience a vision-related decrease in quality of life. Glaucoma treatment in developing countries should
consider clinical, laser, and surgical approaches.
Glaucoma medications do not improve vision, may have important side effects and are relatively expensive.
Thus, compliance can be a major issue, which is related to level of education and socio-economic status of the
patient(9). In a recent study conducted in Brazil, 21.5% of the patients revealed non-adherence to treatment(10).
Currently, some centers are receiving government support in Brazil to provide medications for glaucoma patients
at no cost. We eagerly hope this support to be extended to as many other centers as possible. However, as the
resources are limited, it is important to ensure that treatment is directed towards those patients at risk for
developing functional disability from the disease. It is important to emphasize that there is not only under
diagnosis but also over diagnosis of glaucoma, as up to 50% of the patients treated for glaucoma actually do not
have the disease(11). Good quality diagnostic assessment and proper allocation of resources are therefore essential.
Another requirement for successful medical treatment is adequate longitudinal follow-up through
periodic visits with the attending ophthalmologist. In developing countries, ophthalmology centers are
usually concentrated in urban areas; therefore, people in rural areas may have to travel several hours in order
to obtain medical assistance and this may impair proper care. In fact, a study conducted in Ghana showed that
the chance of developing blindness from glaucoma was much higher in rural areas compared to urban
areas(12). Therefore, investments in proper Ophthalmic care need to tackle this issue, not only for glaucoma but
also all other ophthalmic diseases.
It has been advocated by some that primary surgery would be a good option for glaucoma treatment in the
developing world, because it is a “one shot” solution if well-performed. In India, for example, surgery is often used
as first line treatment(13). However, the procedure is not curative as opposed to cataract surgery, requires long-term
post-operative care, and may be prone to severe complications. The problematic access to medical care in
developing countries makes the management of surgical complications a challenge and it may represent another
potential source of blindness. Laser trabeculoplasty might be an interesting option as primary treatment; however,
its efficacy is limited in the level of intraocular pressure reduction and in the duration of the effect(14-15).
CONCLUSION
There is a strong need to increase the quantity and quality of population-based epidemiologic studies of
the prevalence of glaucoma and burden of the disease in Brazil and other developing countries. Such studies
are essential in order to enable the development of adequate strategies to deal with the problem. Current
strategies to improve detection of disease should aim at increasing awareness of the disease among the
general population and knowledge of risk factors, such as positive family history. Additionally, educational
programs should be designed to improve recognition of the signs of the disease by ophthalmologists and
other medical professionals. Treatment resources should be allocated to those patients at highest risk of
developing functional impairment from the disease and the therapy of choice should take into account
efficacy, adherence to treatment and potential side effects.
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